Manufacturer
RANBAXY (MALAYSIA) SDN. BHD.
Contents
Atorvastatin
Indication
Familial homozygous hypercholesterolaemia, Heterozygous familial hypercholesterolaemia, Mixed dyslipidaemia, Nonfamilial hypercholesterolaemia, Prophylaxis of cardiovascular events in high-risk patients.
Instruction
May be taken with or without food. Avoid excessive consumption (>1 L/day) of grapefruit juice.
Drug interaction
May increase risk of myopathy and rhabdomyolysis with moderate to potent CYP3A4 inhibitors (e.g. HIV and HCV protease inhibitors, itraconazole, ketoconazole, clarithromycin, eryhthromycin, verapamil, diltiazem), fenofibrate, gemfibrozil, ezetimibe, niacin, colchicine, fixed combination of lopinavir/ritonavir. Concomitant use with CYP3A4 inducers (e.g. rifampicin, efavirenz, phenytoin), Al or Mg antacids, and colestipol may reduce plasma concentrations of atorvastatin. May increase serum levels of digoxin and oral contraceptives (e.g. norethindrone, ethinyl estradiol). Potentially Fatal: Concomitant use with ciclosporin, telaprevir, glecaprevir/pibrentasvir and tipranavir/ritonavir combinations may potentiate risk of myopathy or rhabdomyolysis. Coadministration with or within 7 days of stopping systemic fusidic acid may increase risk of fatal rhabdomyolysis.
Malaysia
